JPH09507387A - 遺伝子発現の制御 - Google Patents
遺伝子発現の制御Info
- Publication number
- JPH09507387A JPH09507387A JP7517818A JP51781895A JPH09507387A JP H09507387 A JPH09507387 A JP H09507387A JP 7517818 A JP7517818 A JP 7517818A JP 51781895 A JP51781895 A JP 51781895A JP H09507387 A JPH09507387 A JP H09507387A
- Authority
- JP
- Japan
- Prior art keywords
- double
- helix
- stranded
- region
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一本鎖標的核酸とトリプルヘリックスを形成できるRNAをコードする二本 鎖DNA。 2.少なくとも −標的一本鎖核酸またはその一部分とダブルヘリックスを形成できる第一領域、 −このように形成したダブルヘリックス、またはその部分とトリプルヘリックス を形成できる第二領域、および −2つの領域を連結する1つまたは2つのアーム(このアームは各領域を連続的 、または断続的にすることができる)、 を含む複合RNAをコードすることを特徴とする、請求の範囲第1項に記載の二 本鎖DNA。 3.複合RNAの第一領域がワトソン−クリック型の相互作用により標的一本鎖 核酸とダブルヘリックスを形成し、そして次に第二領域がこのように形成したダ ブルヘリックスと水素結合(フーグスティーンまたは逆フーグスティーン型)に よりトリプルヘリックスを形成することを特徴とする、請求の範囲第1または第 2項に記載の二本鎖DNA。 4.複合RNAの2つの領域がその間にワトソン−クリック型の対合によりダブ ルヘリックスを形成し、そしてこのダブルヘリックスが標的一本鎖核酸と水素結 合(フーグスティーンまたは逆フーグスティーン型)により相互反応し、このよ うにしてトリプルヘリックスを形成することを特徴とする、請求の範囲第1また は第2項に記載の二本鎖DNA。 5.−標的一本鎖核酸またはその部分とダブルヘリックスを形成できる第一領域 、 −このように形成したダブルヘリックス、またはその部分とトリプルヘリックス を形成できる第二領域、および −2つの領域をその末端で連結する2つのアーム、 を含む複合RNAをコードすることを特徴とする、請求の範囲第1項に記載の二 本鎖DNA。 6.−標的一本鎖核酸のオリゴプリン領域とダブルヘリックスを形成できる第一 領域、 −アーム、 −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる第二領域、 −標的とする一本鎖核酸のオリゴピリミジン領域とダブルヘリックスを形成でき る、第一に連結された第三領域、 −第二アーム、および −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる、第三に連結した第四領域、 を含む複合RNAをコードすることを特徴とする、請求の範囲第1項に記載の二 本鎖DNA。 7.アームが3−6個の塩基を含むことを特徴とする、請求の範囲第1ないし第 6項のいずれか1項に記載の二本鎖DNA。 8.RNAが10塩基よりも長い長さ、そして好ましくは15塩基よりも長い長 さを有することをを特徴とする、請求の範囲第1ないし第7項のいずれか1項に 記載の二本鎖DNA。 9.さらに混成RNAの転写を可能にするシグナルを含むことを特徴とする、前 記請求の範囲のいずれか1項に記載の二本鎖DNA。 10.転写シグナルが構成されたものであるか、または制御されることを特徴と する、請求の範囲第9項に記載の二本鎖DNA。 11.RNAポリメラーゼIIIにより特異的に制御される転写プロモーターを含 んで成ることを特徴とする、請求の範囲第10項に記載の二本鎖DNA。 12.一本鎖標的核酸が、例えばmRNA、tRNA、rRNAまたはウイルス RNAから選択され、そして一本鎖または部分的に開いた二本鎖DNAであるこ とを特徴とする、前記請求の範囲のいずれか1項に記載の二本鎖DNA。 13.配列番号2、3、4、5、6、7、8、10、11、13、14、15お よび17の配列から選択されることを特徴とする、前記請求の範囲のいずれか1 項に記載の二本鎖DNA。 14.前記請求の範囲のいずれか1項に記載の二本鎖DNAを含む発現ベクター 。 15.組換えウイルスであることを特徴とする、請求の範囲第14項に記載のベ クター。 16.ウイルスが、アデノウイルス、レトロウイルス、アデノ−伴生ウイルス、 ヘルペスウイルス、サイトメガロウイルスおよびワクシニアウイルスから選択さ れることを特徴とする、請求の範囲第15項に記載のベクター。 17.欠陥ウイルスであることを特徴とする、請求の範囲第15または第16項 のいずれかに記載のベクター。 18.同一または異なる、請求の範囲第1ないし第13項のいずれかに記載の多 数の二本鎖DNAを含むことを特徴とする、請求の範囲第14 ないし第17項のいずれか1項に記載のベクター。 19.前記請求の範囲のいずれか1項に記載の少なくとも1つの二本鎖DNAま たはベクターを含む医薬組成物。 20.一本鎖標的核酸とトリプルヘリックスを形成できるRNAをコードする少 なくとも1つの二本鎖DNAを、DEAE−デキストランと、核タンパク質と、 または脂質との複合体の状態で、裸の状態で、あるいはリポソームまたはナノパ ーティクル中に取り込まれた状態で含む医薬組成物。 21.一本鎖標的核酸とトリプルヘリックスを形成できることを特徴とするRN A。 22.少なくとも: −標的一本鎖核酸またはその一部とダブルヘリックスを形成できる第一領域、 −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる第二領域、および −2つの領域を連結する1つまたは2つのアーム(このアームは各領域を連続的 、または断続的にすることができる)、 を含む複合RNA。 23.−標的一本鎖核酸またはその一部とダブルヘリックスを形成できる第一領 域、 −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる第二領域、および −2つの領域をその末端で連結する2つのアーム、 を含む複合RNA。 24.−標的一本鎖核酸のオリゴプリン領域とダブルヘリックスを形成できる第 一領域、 −アーム、 −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる第二領域、 −標的とする一本鎖核酸のオリゴピリミジン領域とダブルヘリックスを形成でき る、第一に連結された第三領域、 −第二アーム、および −このように形成したダブルヘリックスまたはその一部とトリプルヘリックスを 形成できる、第三に連結した第四領域、 を含む複合RNA。 25.請求の範囲第1ないし第18項のいずれか1項に記載の二本鎖DNAまた はベクターを特別な細胞中へ導入することを含む、特定の細胞中で遺伝子発現を 制御るす方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9315798A FR2714383B1 (fr) | 1993-12-29 | 1993-12-29 | Contrôle de l'expression de gènes. |
FR93/15798 | 1993-12-29 | ||
PCT/FR1994/001536 WO1995018223A1 (fr) | 1993-12-29 | 1994-12-27 | Controle de l'expression de genes |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09507387A true JPH09507387A (ja) | 1997-07-29 |
Family
ID=9454520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7517818A Ceased JPH09507387A (ja) | 1993-12-29 | 1994-12-27 | 遺伝子発現の制御 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6133024A (ja) |
EP (2) | EP0737248B1 (ja) |
JP (1) | JPH09507387A (ja) |
AT (1) | ATE378405T1 (ja) |
AU (1) | AU1388495A (ja) |
CA (1) | CA2180032C (ja) |
DE (1) | DE69435043T2 (ja) |
DK (1) | DK0737248T3 (ja) |
ES (1) | ES2297830T3 (ja) |
FI (1) | FI120740B (ja) |
FR (1) | FR2714383B1 (ja) |
IL (1) | IL112195A (ja) |
NO (1) | NO962707L (ja) |
PT (1) | PT737248E (ja) |
WO (1) | WO1995018223A1 (ja) |
ZA (1) | ZA9410367B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059639A1 (fr) * | 1998-05-19 | 1999-11-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations solides pour administration orale de medicaments relatifs a des genes |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
NZ506648A (en) * | 1998-03-20 | 2003-08-29 | Benitec Australia Ltd | Control of gene expression through introduction of synthetic tandem repeats to reduce translation of mRNA |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6525185B1 (en) | 1998-05-07 | 2003-02-25 | Affymetrix, Inc. | Polymorphisms associated with hypertension |
CA2361201A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
KR20010112944A (ko) * | 1999-04-21 | 2001-12-22 | 이곤 이 버그 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물 |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US20020132257A1 (en) * | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
FR2822476B1 (fr) | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
EP2221377B2 (en) * | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
JP2014510265A (ja) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 |
WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
WO1993012234A1 (en) * | 1991-12-13 | 1993-06-24 | Sri International | Antiviral reagents based on rna-binding proteins |
FR2687411A1 (fr) * | 1992-02-13 | 1993-08-20 | Nice Sophia Antipolis Universi | Vecteur comportant un gene viral transcrit par l'arn polymerase iii, et procede de production intracellulaire d'arn. |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
-
1993
- 1993-12-29 FR FR9315798A patent/FR2714383B1/fr not_active Expired - Lifetime
-
1994
- 1994-12-27 EP EP95905172A patent/EP0737248B1/fr not_active Expired - Lifetime
- 1994-12-27 AT AT95905172T patent/ATE378405T1/de active
- 1994-12-27 DE DE69435043T patent/DE69435043T2/de not_active Expired - Lifetime
- 1994-12-27 EP EP07007057A patent/EP1939290A3/fr not_active Withdrawn
- 1994-12-27 AU AU13884/95A patent/AU1388495A/en not_active Abandoned
- 1994-12-27 DK DK95905172T patent/DK0737248T3/da active
- 1994-12-27 WO PCT/FR1994/001536 patent/WO1995018223A1/fr active IP Right Grant
- 1994-12-27 JP JP7517818A patent/JPH09507387A/ja not_active Ceased
- 1994-12-27 CA CA2180032A patent/CA2180032C/fr not_active Expired - Lifetime
- 1994-12-27 ES ES95905172T patent/ES2297830T3/es not_active Expired - Lifetime
- 1994-12-27 PT PT95905172T patent/PT737248E/pt unknown
- 1994-12-28 ZA ZA9410367A patent/ZA9410367B/xx unknown
- 1994-12-29 IL IL11219594A patent/IL112195A/en not_active IP Right Cessation
-
1996
- 1996-06-26 NO NO962707A patent/NO962707L/no not_active Application Discontinuation
- 1996-06-28 FI FI962693A patent/FI120740B/fi not_active IP Right Cessation
-
1998
- 1998-05-07 US US09/074,357 patent/US6133024A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059639A1 (fr) * | 1998-05-19 | 1999-11-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations solides pour administration orale de medicaments relatifs a des genes |
US6794367B1 (en) | 1998-05-19 | 2004-09-21 | Hisamitsu Pharmaceutical, Inc. | Solid preparations for oral administration of drugs relating to genes |
Also Published As
Publication number | Publication date |
---|---|
CA2180032C (fr) | 2010-08-10 |
IL112195A (en) | 2004-08-31 |
WO1995018223A1 (fr) | 1995-07-06 |
NO962707D0 (no) | 1996-06-26 |
DE69435043T2 (de) | 2008-09-04 |
PT737248E (pt) | 2008-02-25 |
EP1939290A2 (fr) | 2008-07-02 |
ATE378405T1 (de) | 2007-11-15 |
FI962693A0 (fi) | 1996-06-28 |
AU1388495A (en) | 1995-07-17 |
EP1939290A3 (fr) | 2011-07-06 |
CA2180032A1 (fr) | 1995-07-06 |
ES2297830T3 (es) | 2008-05-01 |
IL112195A0 (en) | 1995-03-15 |
DE69435043D1 (de) | 2007-12-27 |
ZA9410367B (en) | 1995-09-20 |
DK0737248T3 (da) | 2008-03-25 |
US6133024A (en) | 2000-10-17 |
FI120740B (fi) | 2010-02-15 |
FI962693A (fi) | 1996-06-28 |
EP0737248A1 (fr) | 1996-10-16 |
FR2714383A1 (fr) | 1995-06-30 |
EP0737248B1 (fr) | 2007-11-14 |
NO962707L (no) | 1996-06-26 |
FR2714383B1 (fr) | 1996-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09507387A (ja) | 遺伝子発現の制御 | |
US20180201921A1 (en) | CRISPRs | |
EP0681482B1 (en) | Localization of therapeutic agents | |
EP0581848B1 (fr) | Oligonucleotides fermes, antisens et sens, et leurs applications | |
US5272065A (en) | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA | |
AU675613B2 (en) | Therapeutic ribozyme compositions | |
WO2019135829A1 (en) | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppressive therapy | |
WO1994016736A9 (en) | Localization of therapeutic agents | |
CA2764158A1 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
JPH08510130A (ja) | 異常スプライシングを阻害するアンチセンスオリゴヌクレオチドと同物質の利用法 | |
JP2002505876A (ja) | Ccr5受容体の発現を阻害することが可能なリボザイム | |
JP2022548308A (ja) | カーゴを標的細胞に送達するための組成物及び方法 | |
US20220290177A1 (en) | Compositions and methods for excision with single grna | |
JP2019517465A (ja) | 溶菌および溶原ウイルスの処理の組成物および方法 | |
JP2020505390A (ja) | Crispr治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス | |
EP3369435B1 (en) | Composition for the treatment of inflammatory joint disease | |
AU2005229159A1 (en) | Therapeutic molecules for modulating stability of VEGF transcripts | |
JP2022548320A (ja) | アポリポタンパク質b(apob)遺伝子発現をモジュレートするための組成物および方法 | |
JP2023517326A (ja) | フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法 | |
EP4083227A1 (en) | Linear dna with enhanced resistance against exonucleases | |
KR20230031852A (ko) | 헌팅턴병을 위한 mirna-485 억제제 | |
JP2000514438A (ja) | Grb2またはCrk1へのリポソームアンチセンスオリゴデオキシヌクレオチド標的化による慢性骨髄性白血病細胞増殖の阻害 | |
JP3728463B2 (ja) | 新規マキシザイム | |
JP2024511207A (ja) | ハンチントン病を治療するためのrna送達システム | |
US20190336617A1 (en) | CRISPRs IN SERIES TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040510 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070620 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070806 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071211 |